Search Results | The Journal of Immunology | American Association of Immunologists

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells

Annalina Tammen, Stefanie Derer, Ralf Schwanbeck, Thies Rösner, Anna Kretschmer, Frank J. Beurskens, Janine Schuurman, Paul W. H. I. Parren, Thomas Valerius

J Immunol (2017) 198 (4): 1585–1594.

DOI: https://doi.org/10.4049/jimmunol.1601268

Published: 15 February 2017

View article

Add to Citation Manager

Journal Articles

Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells

Patrick J. Engelberts, Marleen Voorhorst, Janine Schuurman, Tom van Meerten, Joost M. Bakker, Tom Vink, Wendy J. M. Mackus, Esther C. W. Breij, Stefanie Derer, Thomas Valerius, Jan G. J. van de Winkel, Paul W. H. I. Parren, Frank J. Beurskens

J Immunol (2016) 197 (12): 4829–4837.

DOI: https://doi.org/10.4049/jimmunol.1600811

Published: 15 December 2016

View article

Add to Citation Manager

Includes: Supplementary data

Journal Articles

EGFR antibodies in immunotherapy: complement optimized antibody enhances polymorphonuclear cell mediated killing

Ralf Schwanbeck, Stefanie Derer, Thies Roesner, Christian Kellner, Frank Beurskens, Stefan Lohse, Matthias Peipp, Thomas Valerius

J Immunol (2016) 196 (1_Supplement): 142.4.

DOI: https://doi.org/10.4049/jimmunol.196.Supp.142.4

Published: 01 May 2016

View article

Add to Citation Manager

Journal Articles

A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor Cells

Stefanie Derer, Michael Cossham, Thies Rösner, Christian Kellner, Frank J. Beurskens, Ralf Schwanbeck, Stefan Lohse, Christian Sina, Matthias Peipp, Thomas Valerius

J Immunol (2015) 195 (10): 5077–5087.

DOI: https://doi.org/10.4049/jimmunol.1501458

Published: 15 November 2015

View article

Add to Citation Manager

Includes: Supplementary data

Journal Articles

Epidermal Growth Factor Receptor Targeting IgG3 Triggers Complement-Mediated Lysis of Decay-Accelerating Factor Expressing Tumor Cells through the Alternative Pathway Amplification Loop

Thies Rösner, Stefan Lohse, Matthias Peipp, Thomas Valerius, Stefanie Derer

J Immunol (2014) 193 (3): 1485–1495.

DOI: https://doi.org/10.4049/jimmunol.1400329

Published: 01 August 2014

View article

Add to Citation Manager

Journal Articles

Impact of Epidermal Growth Factor Receptor (EGFR) Cell Surface Expression Levels on Effector Mechanisms of EGFR Antibodies

Stefanie Derer, Philip Bauer, Stefan Lohse, Andreas H. Scheel, Sven Berger, Christian Kellner, Matthias Peipp, Thomas Valerius

J Immunol (2012) 189 (11): 5230–5239.

DOI: https://doi.org/10.4049/jimmunol.1202037

Published: 01 December 2012

View article

Add to Citation Manager

Journal Articles

Mimicking an Induced Self Phenotype by Coating Lymphomas with the NKp30 Ligand B7-H6 Promotes NK Cell Cytotoxicity

Christian Kellner, Tina Maurer, Daniela Hallack, Roland Repp, Jan G. J. van de Winkel, Paul W. H. I. Parren, Thomas Valerius, Andreas Humpe, Martin Gramatzki, Matthias Peipp

J Immunol (2012) 189 (10): 5037–5046.

DOI: https://doi.org/10.4049/jimmunol.1201321

Published: 15 November 2012

View article

Add to Citation Manager

Includes: Supplementary data

Journal Articles

Targeting FcαRI on Polymorphonuclear Cells Induces Tumor Cell Killing through Autophagy

Jantine E. Bakema, Sonja H. Ganzevles, Donna M. Fluitsma, Marco W. Schilham, Robert H. J. Beelen, Thomas Valerius, Stefan Lohse, Martin J. Glennie, Jan Paul Medema, Marjolein van Egmond

J Immunol (2011) 187 (2): 726–732.

DOI: https://doi.org/10.4049/jimmunol.1002581

Published: 15 July 2011

View article

Add to Citation Manager

Includes: Multimedia, Supplementary data

Journal Articles

Recombinant Dimeric IgA Antibodies against the Epidermal Growth Factor Receptor Mediate Effective Tumor Cell Killing

Stefan Lohse, Stefanie Derer, Thomas Beyer, Katja Klausz, Matthias Peipp, Jeanette H. W. Leusen, Jan G. J. van de Winkel, Michael Dechant, Thomas Valerius

J Immunol (2011) 186 (6): 3770–3778.

DOI: https://doi.org/10.4049/jimmunol.1003082

Published: 15 March 2011

View article

Add to Citation Manager

Includes: Supplementary data

Journal Articles

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

Michel de Weers, Yu-Tzu Tai, Michael S. van der Veer, Joost M. Bakker, Tom Vink, Daniëlle C. H. Jacobs, Lukas A. Oomen, Matthias Peipp, Thomas Valerius, Jerry W. Slootstra, Tuna Mutis, Wim K. Bleeker, Kenneth C. Anderson, Henk M. Lokhorst, Jan G. J. van de Winkel, Paul W. H. I. Parren

J Immunol (2011) 186 (3): 1840–1848.

DOI: https://doi.org/10.4049/jimmunol.1003032

Published: 01 February 2011

View article

Add to Citation Manager

Journal Articles

A Recombinant Bispecific Single-Chain Fragment Variable Specific for HLA Class II and FcαRI (CD89) Recruits Polymorphonuclear Neutrophils for Efficient Lysis of Malignant B Lymphoid Cells

Yvonne Guettinger, Karin Barbin, Matthias Peipp, Joerg Bruenke, Michael Dechant, Heike Horner, Doreen Thierschmidt, Thomas Valerius, Roland Repp, Georg H. Fey, Bernhard Stockmeyer

J Immunol (2010) 184 (3): 1210–1217.

DOI: https://doi.org/10.4049/jimmunol.0902033

Published: 30 December 2009

View article

Add to Citation Manager

Journal Articles

Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage

Tanja Schneider-Merck, Jeroen J. Lammerts van Bueren, Sven Berger, Kai Rossen, Patrick H.C. van Berkel, Stefanie Derer, Thomas Beyer, Stefan Lohse, Wim K. Bleeker, Matthias Peipp, Paul W. H. I. Parren, Jan G. J. van de Winkel, Thomas Valerius, Michael Dechant

J Immunol (2010) 184 (1): 512–520.

DOI: https://doi.org/10.4049/jimmunol.0900847

Published: 14 December 2009

View article

Add to Citation Manager

Journal Articles

Tumor Cell Killing Mechanisms of Epidermal Growth Factor Receptor (EGFR) Antibodies Are Not Affected by Lung Cancer-Associated EGFR Kinase Mutations

Matthias Peipp, Tanja Schneider-Merck, Michael Dechant, Thomas Beyer, Jeroen J. Lammerts van Bueren, Wim K. Bleeker, Paul W. H. I. Parren, Jan G. J. van de Winkel, Thomas Valerius

J Immunol (2008) 180 (6): 4338–4345.

DOI: https://doi.org/10.4049/jimmunol.180.6.4338

Published: 15 March 2008

View article

Add to Citation Manager

Journal Articles

Effector Mechanisms of Recombinant IgA Antibodies against Epidermal Growth Factor Receptor

Michael Dechant, Thomas Beyer, Tanja Schneider-Merck, Wencke Weisner, Matthias Peipp, Jan G. J. van de Winkel, Thomas Valerius

J Immunol (2007) 179 (5): 2936–2943.

DOI: https://doi.org/10.4049/jimmunol.179.5.2936

Published: 01 September 2007

View article

Add to Citation Manager

Journal Articles

Polymorphonuclear Granulocytes Induce Antibody-Dependent Apoptosis in Human Breast Cancer Cells

Bernhard Stockmeyer, Thomas Beyer, Winfried Neuhuber, Roland Repp, Joachim R. Kalden, Thomas Valerius, Martin Herrmann

J Immunol (2003) 171 (10): 5124–5129.

DOI: https://doi.org/10.4049/jimmunol.171.10.5124

Published: 15 November 2003

View article

Add to Citation Manager

Journal Articles

Intracellular Domains of Target Antigens Influence Their Capacity to Trigger Antibody-Dependent Cell-Mediated Cytotoxicity

Klaus Tiroch, Bernhard Stockmeyer, Carola Frank, Thomas Valerius

J Immunol (2002) 168 (7): 3275–3282.

DOI: https://doi.org/10.4049/jimmunol.168.7.3275

Published: 01 April 2002

View article

Add to Citation Manager

Journal Articles

Triggering FCα-Receptor I (CD89) Recruits Neutrophils as Effector Cells for CD20-Directed Antibody Therapy

Bernhard Stockmeyer, Michael Dechant, Marjolein van Egmond, Alison L. Tutt, Karuna Sundarapandiyan, Robert F. Graziano, Roland Repp, Joachim R. Kalden, Martin Gramatzki, Martin J. Glennie, Jan G. J. van de Winkel, Thomas Valerius

J Immunol (2000) 165 (10): 5954–5961.

DOI: https://doi.org/10.4049/jimmunol.165.10.5954

Published: 15 November 2000

View article

Add to Citation Manager

NARROW

Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells

Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells

EGFR antibodies in immunotherapy: complement optimized antibody enhances polymorphonuclear cell mediated killing

A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor Cells

Epidermal Growth Factor Receptor Targeting IgG3 Triggers Complement-Mediated Lysis of Decay-Accelerating Factor Expressing Tumor Cells through the Alternative Pathway Amplification Loop

Impact of Epidermal Growth Factor Receptor (EGFR) Cell Surface Expression Levels on Effector Mechanisms of EGFR Antibodies

Mimicking an Induced Self Phenotype by Coating Lymphomas with the NKp30 Ligand B7-H6 Promotes NK Cell Cytotoxicity

Targeting FcαRI on Polymorphonuclear Cells Induces Tumor Cell Killing through Autophagy

Recombinant Dimeric IgA Antibodies against the Epidermal Growth Factor Receptor Mediate Effective Tumor Cell Killing

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

A Recombinant Bispecific Single-Chain Fragment Variable Specific for HLA Class II and FcαRI (CD89) Recruits Polymorphonuclear Neutrophils for Efficient Lysis of Malignant B Lymphoid Cells

Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage

Tumor Cell Killing Mechanisms of Epidermal Growth Factor Receptor (EGFR) Antibodies Are Not Affected by Lung Cancer-Associated EGFR Kinase Mutations

Effector Mechanisms of Recombinant IgA Antibodies against Epidermal Growth Factor Receptor

Polymorphonuclear Granulocytes Induce Antibody-Dependent Apoptosis in Human Breast Cancer Cells

Intracellular Domains of Target Antigens Influence Their Capacity to Trigger Antibody-Dependent Cell-Mediated Cytotoxicity

Triggering FCα-Receptor I (CD89) Recruits Neutrophils as Effector Cells for CD20-Directed Antibody Therapy

Email alerts

Publications

Submit a Manuscript

General Information

Journal Services

Email alerts

Publications

Submit a Manuscript

General Information

Journal Services

This Feature Is Available To Subscribers Only